NASDAQ:SYRE

Spyre Therapeutics Q3 2026 Earnings Results & Report

Spyre Therapeutics logo
$93.47 -4.16 (-4.26%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$93.55 +0.08 (+0.09%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$0.94 versus the -$0.8223 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Spyre Therapeutics EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.8223
Beat/Miss
Missed by -$0.1177
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Q3 2026 Earnings FAQ

Spyre Therapeutics (NASDAQ:SYRE) reported earnings of -$0.94 per share for Q3 2026, missing the consensus estimate of -$0.8223. The report was announced on Tuesday, November 3, 2026.

Spyre Therapeutics Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions.

The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Spyre was formed in 2023 through a business combination with Aeglea BioTherapeutics, which subsequently adopted the Spyre Therapeutics name. The company is based in the United States and is focused on developing treatments for patients with inflammatory bowel disease.

View Spyre Therapeutics Profile